1,910 Shares in Becton, Dickinson and Company (NYSE:BDX) Bought by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,910 shares of the medical instruments supplier’s stock, valued at approximately $461,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Livelsberger Financial Advisory bought a new position in Becton, Dickinson and Company during the third quarter worth about $26,000. Ashton Thomas Securities LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $33,000. Tompkins Financial Corp increased its holdings in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Finally, Opal Wealth Advisors LLC bought a new position in Becton, Dickinson and Company during the second quarter worth $45,000. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BDX. Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Evercore ISI lifted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Trading Down 0.6 %

Shares of NYSE:BDX opened at $224.00 on Friday. The business’s 50 day simple moving average is $235.15 and its 200 day simple moving average is $234.54. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $249.89. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The company has a market capitalization of $64.74 billion, a P/E ratio of 37.71, a P/E/G ratio of 1.68 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.42 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.86%. Becton, Dickinson and Company’s payout ratio is presently 63.97%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.